4 completed, 3 recruiting, 1 terminated, 1 withdrawn. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Recruiting 3, Terminated 1, Withdrawn 1 |
Follow tesamorelin: new trials by email Literature Review of tesamorelin trials Research Report on tesamorelin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) Tesamorelin, Placebo, Standardized lifestyle counseling - Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | Recruiting | Hudson Biotech | 120 | 2026-02-02 | 2026-03-19 |
| Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV Tesamorelin, Placebo, Exercise - HIV-1-infection, Frailty | Phase 2 | Recruiting | Massachusetts General Hospital | 100 | 2025-07-10 | 2026-05-19 |
| Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk Tesamorelin, Identical Placebo - Non-Alcoholic Fatty Liver Disease, Obesity | Phase 2 | Completed | Massachusetts General Hospital | 51 | 2019-01-17 | 2025-11-20 |
| Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury Tesamorelin 2 Milligrams (MG) - Peripheral Nerve Injuries | Phase 2 | Recruiting | Johns Hopkins University | 36 | 2018-06-01 | 2025-11-12 |
| Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons Tesamorelin - Mild Cognitive Impairment | Phase 2 | Completed | University of California, San Diego | 73 | 2017-02-15 | 2026-03-12 |
| Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia Tesamorelin, Placebo - Sleep Disorder, Traumatic Brain Injury | Phase 2 | Withdrawn | National Institute of Nursing Research (NINR) | 2016-10-06 | 2019-11-19 | |
| Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting Tesamorelin, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Terminated | Theratechnologies | 3 | 2011-09-01 | 2022-03-18 |
| Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese Growth hormone releasing hormone (GHRH) 1-44, Placebo - Abdominal Obesity, Growth Hormone Deficiency | Phase 2 | Completed | Massachusetts General Hospital | 60 | 2008-07-01 | 2017-12-13 |
| Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes TH9507 - Type 2 Diabetes | Phase 2 | Completed | Theratechnologies | 55 | 2002-02-01 | 2010-12-21 |
Obesity, Abdominal (3) · Fatty Liver (2) · Non-alcoholic Fatty Liver Disease (2) · Brain Injuries, Traumatic (1) · Cognitive Dysfunction (1) · Diabetes Mellitus, Type 2 (1) · Dwarfism, Pituitary (1) · Fibrosis (1) · Frailty (1) · Muscular Atrophy (1) · Obesity (1) · Peripheral Nerve Injuries (1) · Pulmonary Disease, Chronic Obstructive (1) · Sleep Initiation and Maintenance Disorders (1) · Sleep Wake Disorders (1)
Massachusetts General Hospital (3) · Theratechnologies (2) · Hudson Biotech (1) · Johns Hopkins University (1) · National Institute of Nursing Research (NINR) (1) · University of California, San Diego (1)
United States (5) · China (1)
Fred Sattler, MD (1) · Jessica Gill, Ph.D. (1) · Kristine M. Erlandson, MD (1) · Lindsay T. Fourman, MD (1) · Richard Casaburi, PhD, MD (1) · Ronald J Ellis, MD, PhD (1) · Sami Tuffaha, MD (1) · Steven K. Grinspoon, MD (1)
PMID 23015655, PMID 24178787, PMID 24291224, PMID 28617838, PMID 42419889
R01HL085268 (1)